Skip to main content

31-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The PrE0505 study

Patrick Forde presents the phase 2 PrE0505 trial findings for durvalumab plus chemotherapy in patients with newly diagnosed unresectable malignant pleural mesothelioma, and discusses in light of the PROMISE-meso trial of pembrolizumab in the second-line setting (6:23).

Read transcript

Enriched treatment pathway for non-driver NSCLC

What is it and why do I need it?

Have your say on Medicine Matters

Visit the conference hub

Image Credits